Literature DB >> 7581968

Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy.

Y E Snel1, M E Doerga, R J Brummer, P M Zelissen, M L Zonderland, H P Koppeschaar.   

Abstract

The resting metabolic rate (RMR), and body composition were assessed in 30 growth hormone-deficient (GHD) adults before and after 3 and 6 months of replacement therapy with recombinant human growth hormone (rhGH). In addition, insulin-like growth factor I (IGF-I), IGF binding proteins (IGFBPs) and plasma insulin were measured at baseline and at 6 months in relation to RMR. During 6 months of rhGH replacement therapy, body fat decreased from 18.2 +/- 1.5 (mean +/- SEM) to 14.3 +/- 1.6 kg (p < 0.0001), whereas fat-free mass (FFM) increased from 53.5 +/- 3.3 to 56.3 +/- 3.6 kg (p < 0.0001), RMR increased from 1246 +/- 92 to 1539 +/- 102 kcal/24 h (p < 0.0001) and RMR per kilogram of FFM increased from 23.2 +/- 0.6 to 27.4 +/- 0.5 (p < 0.0001). When RMR data were adjusted for the differences in FFM, it appeared that apart from the increase in FFM, other factors may play a role in the increase in RMR. During rhGH replacement therapy, IGF-I (p < 0.0001) and IGFBP-3 (p = 0.003) levels increased, whereas IGFBP-1 levels decreased significantly (p = 0.004). The FFM explained for about 80% of the variance in RMR. In addition, waist/hip ratio and plasma IGF-I contributed significantly to the explained variance of RMR. This study shows that in GHD adults FFM is the main determinant of RMR and that, next to the increase in FFM, changes in metabolic and hormonal parameters contribute to the increase in RMR during rhGH replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581968     DOI: 10.1530/eje.0.1330445

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

Review 1.  Effects of GH replacement on metabolism and physical performance in GH deficient adults.

Authors:  S K Abdul Shakoor; S M Shalet
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Growth hormone deficiency in the adult.

Authors:  M Doga; S Bonadonna; M Gola; G Mazziotti; A Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 3.  The Safety and Efficacy of Growth Hormone Secretagogues.

Authors:  John T Sigalos; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-04-08

4.  Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2.

Authors:  Esteban N Gurzov; Melanie Tran; Manuel A Fernandez-Rojo; Troy L Merry; Xinmei Zhang; Yang Xu; Atsushi Fukushima; Michael J Waters; Matthew J Watt; Sofianos Andrikopoulos; Benjamin G Neel; Tony Tiganis
Journal:  Cell Metab       Date:  2014-06-19       Impact factor: 27.287

Review 5.  Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Yingxuan Wang; Guixia Wang
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

6.  Subjects with isolated GH deficiency due to a null GHRHR mutation eat proportionally more, but healthier than controls.

Authors:  Alécia A Oliveira-Santos; Roberto Salvatori; Elenilde Gomes-Santos; João A M Santana; Ângela C G B Leal; Rita A A Barbosa; Carla R P Oliveira; Anita H O Souza; Eugênia H O Valença; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2015-06-23       Impact factor: 3.633

Review 7.  [Growth hormone therapy in adults. Attempt to assess a decade of use].

Authors:  M Faust; C J Strasburger
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

Review 8.  Pharmacotherapy for childhood obesity: present and future prospects.

Authors:  R Sherafat-Kazemzadeh; S Z Yanovski; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2012-08-28       Impact factor: 5.095

Review 9.  An evolving scientific basis for the prevention and treatment of pediatric obesity.

Authors:  P T Katzmarzyk; S Barlow; C Bouchard; P M Catalano; D S Hsia; T H Inge; C Lovelady; H Raynor; L M Redman; A E Staiano; D Spruijt-Metz; M E Symonds; M Vickers; D Wilfley; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2014-03-25       Impact factor: 5.095

10.  Efficacy and safety of sustained-release recombinant human growth hormone in Korean adults with growth hormone deficiency.

Authors:  Youngsook Kim; Jae Won Hong; Yoon-Sok Chung; Sung-Woon Kim; Yong-Wook Cho; Jin Hwa Kim; Byung-Joon Kim; Eun Jig Lee
Journal:  Yonsei Med J       Date:  2014-07       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.